RecruitingNCT05202951
Chronic Pain and Hemophilia
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Clermont-Ferrand
- Principal Investigator
- Aurélien LEBRETONUniversity Hospital, Clermont-Ferrand
- Intervention
- questionnaires(other)
- Enrollment
- 350 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (10)
- CHU de Bordeaux, Bordeaux, France
- Centre Hospitalier Universitaire de Caen Normandie, Caen, France
- CH Métropole Savoie, Chambéry, France
- CHU de Clermont-Ferrand, Clermont-Ferrand, France
- CHU de Grenoble, Grenoble, France
- CHU de LILLE, Lille, France
- Hospices Civils de Lyon, Lyon, France
- Centre Hospitalier Universitaire de Nantes, Nantes, France
- CHU de Saint-Etienne, Saint-Etienne, France
- CHU de TOULOUSE, Toulouse, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05202951 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE4NCT06940830Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaSwedish Orphan Biovitrum
- RECRUITINGPHASE1NCT06703606A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.Pfizer
- RECRUITINGPHASE3NCT06833983To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia AGritgen Therapeutics Co., Ltd.